{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:13:47Z","timestamp":1789902827774,"version":"4.0.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007102","name":"Zagazig University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007102","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Previous studies have demonstrated an increased risk of developing Parkinson\u2019s disease (PD) in patients with type 2 diabetes mellitus (T2DM), as well as more severe and rapid motor and non-motor deterioration in diabetic PD patients compared to their non-diabetic counterparts. Additional research has suggested that diabetic subjects treated with glucagon-like peptide-1 (GLP-1) receptor agonists exhibit a reduced incidence of PD compared to those receiving other anti-diabetic medications. GLP-1 receptor agonists are FDA-approved therapies for T2DM, and recent studies have explored their potential as repurposed treatments for neurodegenerative diseases, including PD, AD, and ALS, as well as cerebrovascular disorders. This systematic review aims to assess the available literature on the efficacy and safety profiles of GLP-1 receptor agonists in PD management. A comprehensive search of PubMed, Scopus, CENTRAL, Web of Science, Embase, and ClinicalTrials.gov was conducted to identify relevant studies. The primary outcomes of this review include motor impairment in PD, as assessed by MDS-UPDRS Part III, as well as motor complications (Part IV) and motor experiences of daily living (Part II), and the incidence of gastrointestinal and systemic side effects. Meta-analysis showed that GLP-1 receptor agonists significantly improved motor function, as reflected by MDS-UPDRS Part III scores in the ON state (mean difference\u2009=\u2009\u2212\u20092.88; p\u2009=\u20090.01; I<jats:sup>2<\/jats:sup>\u2009=\u200930%), although they were associated with a higher incidence of adverse events across all safety outcomes. Findings and conclusions of this review will contribute to a clearer understanding of the therapeutic potential of GLP-1 receptor agonists in PD, guiding future clinical research and treatment strategies.<\/jats:p>","DOI":"10.1186\/s13098-025-01888-1","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T08:55:59Z","timestamp":1755939359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["GLP-1 receptor agonists in Parkinson\u2019s disease: an updated comprehensive systematic review with meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6387-623X","authenticated-orcid":false,"given":"Mohamed Mohsen","family":"Helal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"AbouShawareb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omarfayez Hussein","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roaa","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmna","family":"Zain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S. A.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr K.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"1888_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol. 2021;20:385\u201397.","journal-title":"Lancet Neurol"},{"key":"1888_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"GBD 2016 Parkinson\u2019s Disease Collaborators","year":"2018","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939\u201353.","journal-title":"Lancet Neurol"},{"key":"1888_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nrn1868","volume":"7","author":"PM Abou-Sleiman","year":"2006","unstructured":"Abou-Sleiman PM, Muqit MMK, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson\u2019s disease. Nat Rev Neurosci. 2006;7:207\u201319.","journal-title":"Nat Rev Neurosci"},{"key":"1888_CR4","volume-title":"Parkinson\u2019s disease: pathogenesis and clinical aspects","author":"A Kouli","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan W-L. Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson\u2019s disease: pathogenesis and clinical aspects. Brisbane: Codon Publications; 2018."},{"key":"1888_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2023.110672","volume":"199","author":"C Dai","year":"2023","unstructured":"Dai C, Tan C, Zhao L, Liang Y, Liu G, Liu H, Zhong Y, Liu Z, Mo L, Liu X, Chen L. Glucose metabolism impairment in Parkinson\u2019s disease. Brain Res Bull. 2023;199: 110672.","journal-title":"Brain Res Bull"},{"key":"1888_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030740","author":"C-T Hong","year":"2020","unstructured":"Hong C-T, Chen K-Y, Wang W, Chiu J-Y, Wu D, Chao T-Y, Hu C-J, Chau K-YD, Bamodu OA. Insulin resistance promotes Parkinson\u2019s disease through aberrant expression of \u03b1-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9030740.","journal-title":"Cells"},{"key":"1888_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/WCO.0000000000001166","volume":"36","author":"R Wang","year":"2023","unstructured":"Wang R, Shih LC. Parkinson\u2019s disease - current treatment. Curr Opin Neurol. 2023;36:302\u20138.","journal-title":"Curr Opin Neurol"},{"key":"1888_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/mds.29298","volume":"38","author":"PW Cullinane","year":"2023","unstructured":"Cullinane PW, de Pablo Fernandez E, K\u00f6nig A, Outeiro TF, Jaunmuktane Z, Warner TT. Type 2 diabetes and parkinson\u2019s disease: a focused review of current concepts. Mov Disord. 2023;38:162\u201377.","journal-title":"Mov Disord"},{"key":"1888_CR9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/mds.26734","volume":"31","author":"P Svenningsson","year":"2016","unstructured":"Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, Ludvigsson JF. Reduced incidence of Parkinson\u2019s disease after dipeptidyl peptidase-4 inhibitors-a nationwide case-control study. Mov Disord. 2016;31:1422\u20133.","journal-title":"Mov Disord"},{"key":"1888_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052687","author":"M Michailidis","year":"2022","unstructured":"Michailidis M, Moraitou D, Tata DA, Kalinderi K, Papamitsou T, Papaliagkas V. Alzheimer\u2019s disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer\u2019s disease and type 2 diabetes. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23052687.","journal-title":"Int J Mol Sci"},{"key":"1888_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbr.2015.07.021","volume":"293","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Chen Y, Li L, H\u00f6lscher C. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson\u2019s disease mouse model. Behav Brain Res. 2015;293:107\u201313.","journal-title":"Behav Brain Res"},{"key":"1888_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-2094-5-19","volume":"5","author":"A Harkavyi","year":"2008","unstructured":"Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson\u2019s disease. J Neuroinflammation. 2008;5:19.","journal-title":"J Neuroinflammation"},{"key":"1888_CR13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1172\/JCI57256","volume":"122","author":"TR Bomfim","year":"2012","unstructured":"Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel J-C, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease- associated A\u03b2 oligomers. J Clin Invest. 2012;122:1339\u201353.","journal-title":"J Clin Invest"},{"key":"1888_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906.","journal-title":"Int J Surg"},{"key":"1888_CR15","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions\u00a0version 6.5\u00a0(updated August 2024). Cochrane; 2024."},{"key":"1888_CR16","doi-asserted-by":"crossref","unstructured":"Hogg E, Wu T, Bresee C, Wertheimer J, Malatt C, Tan E, Pomeroy H, Nuno M, Wyse R & Tagliati M. A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson\u2019s Disease. SSRN Journal; 2022.","DOI":"10.2139\/ssrn.4212371"},{"key":"1888_CR17","unstructured":"Li T, Higgins JPT, Deeks JJ. Chapter 5: Collecting data [last updated October 2019]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. cochrane.org\/handbook"},{"key":"1888_CR18","unstructured":"McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J. Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. cochrane.org\/handbook."},{"key":"1888_CR19","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease","year":"2003","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease. The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738\u201350.","journal-title":"Mov Disord"},{"key":"1888_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11136-011-9995-3","volume":"21","author":"C Sj\u00f6dahl Hammarlund","year":"2012","unstructured":"Sj\u00f6dahl Hammarlund C, Nilsson MH, Hagell P. Measuring outcomes in Parkinson\u2019s disease: a multi-perspective concept mapping study. Qual Life Res. 2012;21:453\u201363.","journal-title":"Qual Life Res"},{"key":"1888_CR21","unstructured":"Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, Noel-Storr A, Paynter R, Rader T, Thomas J, Wieland LS. Chapter 4: Searching for and selecting studies [last updated March 2025]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5.1 Cochrane; 2025. cochrane.org\/handbook."},{"key":"1888_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10654-019-00576-5","volume":"35","author":"T Muka","year":"2020","unstructured":"Muka T, Glisic M, Milic J, Verhoog S, Bohlius J, Bramer W, Chowdhury R, Franco OH. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. Eur J Epidemiol. 2020;35:49\u201360.","journal-title":"Eur J Epidemiol"},{"key":"1888_CR23","unstructured":"EndNote - Citation & Reference Management Tool. https:\/\/endnote.com\/?srsltid=AfmBOoqB-MAtazd1KSYVBrKyYu8mD4vpDWwRnu5cgLBjM45y8rIJKIwM"},{"key":"1888_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"1888_CR25","unstructured":"\u201cautomeris.io: Computer vision assisted data extraction from charts using WebPlotDigitizer. https:\/\/automeris.io\/. Accessed 25 Aug 2024."},{"key":"1888_CR26","unstructured":"\"Meta-Analysis Accelerator | Your Meta-Analysis Conversion Tool. https:\/\/meta-converter.com"},{"key":"1888_CR27","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664\u201375.","journal-title":"Lancet"},{"key":"1888_CR28","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Invest. 2013;123:2730\u20136.","journal-title":"J Clin Invest"},{"key":"1888_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.3068","author":"C Malatt","year":"2022","unstructured":"Malatt C, Wu T, Bresee C, Hogg E, Wertheimer J, Tan E, Pomeroy H, Obialisi G, Tagliati M. Liraglutide improves non-motor function and activities of daily living in patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial (P9\u201311.005). Neurology. 2022. https:\/\/doi.org\/10.1212\/WNL.98.18_supplement.3068.","journal-title":"Neurology"},{"key":"1888_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Kieburtz K. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23:37\u201345.","journal-title":"Lancet Neurol"},{"key":"1888_CR31","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Malt\u00eate D, Derkinderen P, Hou\u00e9to J-L, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carri\u00e8re N, Catala H, Colin O, Corvol J-C, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, LIXIPARK Study Group. Trial of lixisenatide in early parkinson\u2019s disease. N Engl J Med. 2024;390:1176\u201385.","journal-title":"N Engl J Med"},{"key":"1888_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"1888_CR33","unstructured":"Higgins JPT, Li T, Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024. cochrane.org\/handbook."},{"key":"1888_CR34","unstructured":"Safety and Efficacy of Liraglutide in\u00a0Parkinson\u2019s\u00a0Disease. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT02953665?cond=Parkinson%27s%20Disease&term=glp-1&rank=10"},{"key":"1888_CR35","unstructured":"The Cochrane Collaboration. Review Manager (RevMan)[computerprogram]. Version 5.4. 2020. https:\/\/login.cochrane.org\/realms\/cochrane\/protocol\/openid-connect\/auth?client_id=revman-web&redirect_uri=https%3A%2F%2Frevman.cochrane.org&response_type=code&scope=openid%20profile&nonce=8ccf28f5aeff2e02c6dfb482c52de44befKjVOtjQ&state=6d9731f6d393efb414301a963b42ed8ecajw3WtuZ&code_challenge=M3yCEQMDg20WA-gKqE_CUCWqIa8q0ZUC2cMWkx-ucsw&code_challenge_method=S256"},{"key":"1888_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JPD-181329","volume":"8","author":"D Athauda","year":"2018","unstructured":"Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene SS, Chowdhury K, Aviles-Olmos I, Limousin P, Foltynie T. What effects might Exenatide have on non-motor symptoms in Parkinson\u2019s disease: a post hoc analysis. J Parkinsons Dis. 2018;8:247\u201358.","journal-title":"J Parkinsons Dis"},{"key":"1888_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease. J Parkinsons Dis. 2014;4:337\u201344.","journal-title":"J Parkinsons Dis"},{"key":"1888_CR38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/ejn.14096","volume":"49","author":"D Athauda","year":"2019","unstructured":"Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I, Chowdhury K, Skene SS, Limousin P, Foltynie T. Post hoc analysis of the Exenatide-PD trial-factors that predict response. Eur J Neurosci. 2019;49:410\u201321.","journal-title":"Eur J Neurosci"},{"key":"1888_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3233\/JPD-171192","volume":"7","author":"D Athauda","year":"2017","unstructured":"Athauda D, Wyse R, Brundin P, Foltynie T. Is exenatide a treatment for Parkinson\u2019s disease? J Parkinsons Dis. 2017;7:451\u20138.","journal-title":"J Parkinsons Dis"},{"key":"1888_CR40","doi-asserted-by":"crossref","unstructured":"Athauda D, Budnik N, Chowdhury K, Skene S, Foltynie T. The effect of exenatide on specific non-motor symptoms in Parkinson\u2019s disease\u2014a post-hoc analysis. In: European Journal of Neurology. Issue S2 edition. Vol. 25. Abstracts of the 4th congress of the European academy of neurology, Lisbon, Portugal, 2018, 2018:309.","DOI":"10.3233\/JPD-181329"},{"key":"1888_CR41","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jalz.2013.12.005","volume":"10","author":"T Foltynie","year":"2014","unstructured":"Foltynie T, Aviles-Olmos I. Exenatide as a potential treatment for patients with Parkinson\u2019s disease: first steps into the clinic. Alzheimers Dement. 2014;10:S38-46.","journal-title":"Alzheimers Dement"},{"key":"1888_CR42","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoupou Z, Djamshidian A, Kahan J, Ell P, et al. Exenatide and non motor symptoms In Parkinson\u2019s disease (PD) [abstract]. In: Movement Disorders. Vol. 29 Suppl 1 6:12. 2014."},{"key":"1888_CR43","unstructured":"Aviles-Olmos I & Kefalopoulou Z (2012) Aviles-Olmos I, Kefalopoulou Z, Djamshidian A, Limousin P, Dickson J, Lees A, et al. An open label, single site, 12 month, phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (exenatide) in the treatment of patients with moderate severity Parkinson\u2019s disease [abstract]. Movement Disorders 2012;27(Suppl 1:343). Movement \u2026."},{"key":"1888_CR44","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Exenatide and motor symptoms in Parkinson\u2019s disease (PD) [abstract]. In: Movement Disorders. Vol. 29 Suppl 1:611; 2014."},{"key":"1888_CR45","unstructured":"Effects of Exenatide on Motor Function and the Brain. ClinicalTrials.gov Identifier: NCT03456687. https:\/\/www.clinicaltrials.gov\/study\/NCT03456687?cond=Parkinson%27s%20Disease&term=glp-1&rank=1"},{"key":"1888_CR46","unstructured":"Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson\u2019s Disease (Exenatide-PD3). ClinicalTrials.gov Identifier: NCT04232969. https:\/\/clinicaltrials.gov\/study\/NCT04232969"},{"key":"1888_CR47","unstructured":"SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson\u2019s Disease. ClinicalTrials.gov Identifier: NCT04269642. https:\/\/clinicaltrials.gov\/study\/NCT04269642?term=AREA%5BConditionSearch%5D(Neurodegenerative%20Diseases)%20AND%20AREA%5BInterventionSearch%5D(exendin-4)&rank=9"},{"key":"1888_CR48","unstructured":"GLP1R in Parkinson\u2019s Disease (GIPD). ClinicalTrials.gov Identifier: NCT03659682. https:\/\/clinicaltrials.gov\/study\/NCT03659682"},{"key":"1888_CR49","unstructured":"Exenatide Treatment in Parkinson\u2019s Disease. ClinicalTrials.gov Identifier: NCT04305002. https:\/\/clinicaltrials.gov\/study\/NCT04305002"},{"key":"1888_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2169\/internalmedicine.8940-21","volume":"62","author":"H Murakami","year":"2023","unstructured":"Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent advances in drug therapy for Parkinson\u2019s disease. Intern Med. 2023;62:33\u201342.","journal-title":"Intern Med"},{"key":"1888_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/npjparkd.2016.20","volume":"2","author":"M Murata","year":"2016","unstructured":"Murata M, Mihara M, Hasegawa K, Jeon B, Tsai C-H, Nishikawa N, Oeda T, Yokoyama M, Robieson WZ, Ryman D, Eaton S, Chatamra K, Benesh J. Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson\u2019s disease patients. NPJ Parkinsons Dis. 2016;2: 16020.","journal-title":"NPJ Parkinsons Dis"},{"key":"1888_CR52","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/mds.28322","volume":"36","author":"A Takeda","year":"2021","unstructured":"Takeda A, Takahashi R, Tsuboi Y, Nomoto M, Maeda T, Nishimura A, Yoshida K, Hattori N. Randomized, controlled study of opicapone in Japanese Parkinson\u2019s patients with motor fluctuations. Mov Disord. 2021;36:415\u201323.","journal-title":"Mov Disord"},{"key":"1888_CR53","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/mds.29122","volume":"37","author":"D Athauda","year":"2022","unstructured":"Athauda D, Evans J, Wernick A, Virdi G, Choi ML, Lawton M, Vijiaratnam N, Girges C, Ben-Shlomo Y, Ismail K, Morris H, Grosset D, Foltynie T, Gandhi S. The impact of type 2 diabetes in Parkinson\u2019s disease. Mov Disord. 2022;37:1612\u201323.","journal-title":"Mov Disord"},{"key":"1888_CR54","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3233\/JPD-212725","volume":"11","author":"K Komici","year":"2021","unstructured":"Komici K, Femminella GD, Bencivenga L, Rengo G, Pagano G. Diabetes mellitus and Parkinson\u2019s disease: a systematic review and meta-analyses. J Parkinsons Dis. 2021;11:1585\u201396.","journal-title":"J Parkinsons Dis"},{"key":"1888_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073812","author":"K Kalinderi","year":"2024","unstructured":"Kalinderi K, Papaliagkas V, Fidani L. GLP-1 receptor agonists: a new treatment in Parkinson\u2019s disease. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25073812.","journal-title":"Int J Mol Sci"},{"key":"1888_CR56","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1523\/JNEUROSCI.23-07-02939.2003","volume":"23","author":"H Yamamoto","year":"2003","unstructured":"Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci. 2003;23:2939\u201346.","journal-title":"J Neurosci"},{"key":"1888_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2019.104583","volume":"131","author":"EA Elbassuoni","year":"2019","unstructured":"Elbassuoni EA, Ahmed RF. Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson\u2019s with pre-existing diabetes. Neurochem Int. 2019;131: 104583.","journal-title":"Neurochem Int"},{"key":"1888_CR58","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00125-023-06072-6","volume":"67","author":"R Dhanapalaratnam","year":"2024","unstructured":"Dhanapalaratnam R, Issar T, Lee ATK, Poynten AM, Milner K-L, Kwai NCG, Krishnan AV. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia. 2024;67:561\u20136.","journal-title":"Diabetologia"},{"key":"1888_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1268619","volume":"14","author":"C Liu","year":"2023","unstructured":"Liu C, Wu T, Ren N. Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy. Front Endocrinol (Lausanne). 2023;14: 1268619.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1888_CR60","volume":"7","author":"CA Mulvaney","year":"2020","unstructured":"Mulvaney CA, Duarte GS, Handley J, Evans DJ, Menon S, Wyse R, Emsley HC. GLP-1 receptor agonists for Parkinson\u2019s disease. Cochrane Database Syst Rev. 2020;7: CD012990.","journal-title":"Cochrane Database Syst Rev"},{"key":"1888_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107220","volume":"130","author":"MB de Albuquerque","year":"2025","unstructured":"de Albuquerque MB, Nunes LEDB, de Oliveira Maldonado JV, Melo Ferreira DG, Margato MM, Rabelo LV, Valen\u00e7a MM, Oliveira Cordeiro LH. GLP-1 receptor agonists for Parkinson\u2019s disease: an updated meta-analysis. Parkinsonism Relat Disord. 2025;130: 107220.","journal-title":"Parkinsonism Relat Disord"},{"key":"1888_CR62","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","volume":"33","author":"D Erbil","year":"2019","unstructured":"Erbil D, Eren CY, Demirel C, K\u00fc\u00e7\u00fcker MU, Solaro\u011flu I, Eser HY. GLP-1\u2019s role in neuroprotection: a systematic review. Brain Inj. 2019;33:734\u2013819.","journal-title":"Brain Inj"},{"key":"1888_CR63","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","volume":"356","author":"KT Watson","year":"2019","unstructured":"Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL. Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease. Behav Brain Res. 2019;356:271\u20138.","journal-title":"Behav Brain Res"},{"key":"1888_CR64","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3233\/ADR-230181","volume":"8","author":"Y Liang","year":"2024","unstructured":"Liang Y, Dor\u00e9 V, Rowe CC, Krishnadas N. Clinical evidence for GLP-1 receptor agonists in Alzheimer\u2019s disease: a systematic review. ADR. 2024;8:777\u201389.","journal-title":"ADR"},{"key":"1888_CR65","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/acn3.51580","volume":"9","author":"J-Y Li","year":"2022","unstructured":"Li J-Y, Cui L-Y, Sun X-H, Shen D-C, Yang X-Z, Liu Q, Liu M-S. Alterations in metabolic biomarkers and their potential role in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2022;9:1027\u201338.","journal-title":"Ann Clin Transl Neurol"},{"key":"1888_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105059","author":"A Mo\u021b\u0103\u021b\u0103ianu","year":"2024","unstructured":"Mo\u021b\u0103\u021b\u0103ianu A, M\u0103nescu IB, \u0218erban G, B\u0103rcu\u021bean L, Ion V, B\u0103la\u0219a R, Andone S. Exploring the role of metabolic hormones in amyotrophic lateral sclerosis. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25105059.","journal-title":"Int J Mol Sci"},{"key":"1888_CR67","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archneur.60.4.529","volume":"60","author":"NJ Diederich","year":"2003","unstructured":"Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003;60:529\u201333.","journal-title":"Arch Neurol"},{"key":"1888_CR68","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1212\/WNL.39.9.1187","volume":"39","author":"SG Diamond","year":"1989","unstructured":"Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Effect of age at onset on progression and mortality in Parkinson\u2019s disease. Neurology. 1989;39:1187\u201390.","journal-title":"Neurology"},{"key":"1888_CR69","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1212\/01.wnl.0000183359.50822.f2","volume":"65","author":"G Alves","year":"2005","unstructured":"Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology. 2005;65:1436\u201341.","journal-title":"Neurology"},{"key":"1888_CR70","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20:8661\u201372.","journal-title":"Alzheimers Dement"},{"key":"1888_CR71","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_3_24","volume":"66","author":"R Maiti","year":"2024","unstructured":"Maiti R, Mishra A, Jena M, Maji S, Padhan M, Mishra BR. Efficacy and safety of dasotraline in attention-deficit hyperactivity disorder: a systematic review and meta-analysis. Indian J Psychiatry. 2024;66:326\u201335.","journal-title":"Indian J Psychiatry"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01888-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01888-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01888-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:25:26Z","timestamp":1757449526000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01888-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1888"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01888-1","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"14 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and informed consent were not required for this study, as it did not involve human participants or material.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"352"}}